HCRN-GI21-499
A Phase Ib/II Study of Sotorasib Combined with Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer
HCRN-LUN17-302
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302
HCRN-LUN17-126
Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients
BTCRC-GI19-400
Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400
HCRN-BRE19-433
A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)
HCRN-BRE20-442
Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
BRE12-158
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.
HCRN-ESO17-325
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
HCRN-CUP16-268
Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)
HCRN-GI14-191
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy with Ginseng for Patients on Treatment with Regorafenib: HCRN GI14-191.
HCRN-GI14-186
A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186
HCRN-GI14-198
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
HCRN-GI15-225
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
HCRN-GI16-263
A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263
HCRN-GI17-319
A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinoma
HCRN-GI19-414
Molecularly Driven, Immune-Based, Maintenance Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma
HCRN-GI19-405
A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
HCRN-GU14-182
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182
HCRN-GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
HCRN-GU15-215
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
HCRN-GU15-217
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
BTCRC-GU16-043
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
HCRN-GU15-262
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
HCRN-GU17-289
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)
HCRN-GU17-295
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
HCRN-GU17-294
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
HCRN-GU15-223
Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223
HCRN-GU17-326
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
HCRN-LUN15-299
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-299
HCRN-LUN14-179
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
HCRN-LUN17-321
A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
HCRN-LUN18-357
Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer
HCRN-LUN15-233
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous, Non-squamous or Not Otherwise Specified NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
HCRN-LUN19-427
Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases (HCRN LUN19-427)
HCRN-MEL16-261
MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma
MMP-MEL18-372
Phase 1B/2 Study of PAC-1 and Entrectinib for Patients with Metastatic Uveal Melanoma
TBCRC029
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
TBCRC035
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
BTCRC-BRE15-016
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
BTCRC-GI15-015
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-015
BTCRC-GI13-002
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
BTCRC-GI18-149
Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
BTCRC-GU14-003
Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
BTCRC-GU16-051
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
BTCRC-GU19-404
A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer Big Ten Cancer Research Consortium BTCRC-GU19-404
BTCRC-GYN15-013
Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
BTCRC-HEM15-028
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028
BTCRC-HEM16-085
Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
